Risk compensation and STI incidence in PrEP programmes.

[1]  M. Hellard,et al.  Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. D. de Wit,et al.  Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17. , 2018, The lancet. HIV.

[3]  A. Pozniak,et al.  Rapidly declining HIV infection in MSM in central London. , 2017, The lancet. HIV.

[4]  H. Rees,et al.  When are declines in condom use while using PrEP a concern? Modelling insights from a Hillbrow, South Africa case study , 2017, Journal of the International AIDS Society.

[5]  D. Murphy,et al.  Individual Versus Community-Level Risk Compensation Following Preexposure Prophylaxis of HIV , 2017, American journal of public health.

[6]  C. Portillo,et al.  Does pre‐exposure prophylaxis for HIV prevention in men who have sex with men change risk behaviour? A systematic review , 2017, Journal of clinical nursing.

[7]  R. Grant,et al.  Effectiveness and safety of oral HIV preexposure prophylaxis for all populations , 2016, AIDS.

[8]  Fridulv Sagberg,et al.  Risk Compensation and Bicycle Helmets , 2011, Risk analysis : an official publication of the Society for Risk Analysis.

[9]  Till Bärnighausen,et al.  Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. , 2014, The Lancet. Global health.

[10]  Nicholas L. Wilson,et al.  Is Sex Like Driving? HIV Prevention and Risk Compensation. , 2014, Journal of development economics.

[11]  Richard G. White,et al.  Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. , 2013, The Lancet. Global health.